Patients can present with undiagnosed sleep disorders. Modest fatigue can impair their neurological, functional and psychological capacities. Four patients demonstrated improved functioning on modafinil, during the months required for a complete sleep evaluation, specialist consults and successful treatment. Sleep disorders increase morbidity or mortality until definitive diagnosis and full treatment. In four patients, modafinil was immediately useful as a bridging medication over 3-7 months until final successful diagnosis and treatment. Even one month of significant fatigue is unacceptable. For example, driving a motor vehicle is dangerous with some sleep disorders. Falling asleep driving or involuntary “minisleep” at the wheel is a common cause of motor vehicle accidents.1 In the United States, sleep causes at least 56, 000 motor vehicle crashes each year, resulting in 1, 550 deaths.2 Over a year, 10% of men and 4% of women admitted to falling asleep while driving.3 Insight into drowsiness can be flawed, lagging behind electroencephalographic and other evidence that the process of falling asleep has actually started.4 In clinical care, the patient may be sleepy or fatigued, but not a clear risk to drive or work. Further, many occupations do not allow for fatigue, sleepiness and errors, e.g., truck drivers, heavy construction operators, nurses dispensing medications, pilots, boat captains, military and police personnel using dangerous equipment, and childcare workers with children. Modafinil was used because it may be more selective than traditional stimulants, has a low abuse potential, is already used in many specific sleep disorders, and has a reasonable safety record. Modafinil's mechanism as a waking agent appears to be a more selective than amphetamine or methylphenidate in cats, 5 possibly causing less emotional side effects in humans, e.g., agitation and rebound depression. Perhaps due to this proposed selectivity, modafinil receives low ratings for abuse desirability, 6 and with a low solubility in water and instability at high temperatures, I.V. injections and smoking were less likely. 7 These are some reasons that modafinil might be considered in light of the non-specificity and addiction potential of traditional stimulants. Modafinil has cognitive benefits in aviation alertness and functioning. 8, 9 It decreases fatigue in narcolepsy, obstructive sleep apnea, Parkinson's disease, multiple sclerosis, stroke and fibromyalgia.10,11,12,13,14,15 Also, medically fragile patients seemed to tolerate modafinil. Our patients were much healthier than those treated with Parkinson's disease, stroke and multiple sclerosis. These private patients were all waiting for a sleep specialist appointment. They read handouts on the common use of modafinil, e.g., narcolepsy. However, they understood they were trying it for the off-label purpose of daytime sleepiness. Rare questions were answered to their satisfaction.
Read full abstract